TEVA · Healthcare
Teva Pharmaceutical Industries
33/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
company insiders are selling
Hedge funds
60
Congress
No data
Insiders
0
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$42.8B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NYSE
About TEVA PHARMACEUTICAL INDUSTRIES
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system…
Who's behind the signal
Every informed buyer we can see on TEVA, across all three feeds.
Hedge funds · 10
Greenlight Capital (Einhorn)
New position
Point72 (Steve Cohen)
New position
Millennium Management (Englander)
New position
Bridgewater Associates (Dalio)
Increased +50%
Tudor Investment (Paul Tudor Jones)
Increased +9%
AQR Capital Management
Increased +9%
+4 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
Company insiders
Selling
Recent sells39
Congressional trades · 4 on record
Disclosures from 2016-10-19 to 2020-11-13
The newest disclosure we hold for this stock is 2020-11-13.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2020-11-13 | Greg Gianforte · R-MT | House | Bought | $15,001 - $50,000 |
| 2020-05-07 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
| 2017-06-15 | Patty Murray · D-WA | Senate | Sold | $1,001 - $15,000 |
| 2016-10-19 | Angus S. King, Jr. · I-ME | Senate | Sold | $1,001 - $15,000 |
Not a model pick — but on our radar.
TEVA PHARMACEUTICAL INDUSTRIES isn't in the top-10 model right now, but 10 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
10
Investors
3
New positions
3
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
0.1%
Position change
NEW
0.1% of Greenlight Capital's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
NEW
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Millennium Management's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
+50%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.2×
% of portfolio
0.1%
Position change
+9%
0.1% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+9%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
5.4%
Position change
−60%
5.4% of Glenview Capital Mgmt's portfolio
Trust weight: 1.6×
% of portfolio
2.4%
Position change
−60%
2.4% of Duquesne Family Office's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−35%
0.0% of ARK Invest's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−78%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to TEVA PHARMACEUTICAL INDUSTRIES
No insider trades found in the last 90 days
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TEVA PHARMACEUTICAL INDUSTRIES or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订